Weight, Lipids, Glucose, and Behavioral Measures With Ziprasidone Treatment in a Population With Mental Retardation
J Clin Psychiatry 2003;64(1):60-62
© Copyright 2017 Physicians Postgraduate Press, Inc.
Purchase This PDF for $40.00
If you are not a paid subscriber, you may purchase the PDF.
(You'll need the free Adobe Acrobat Reader.)
Receive immediate full-text access to JCP. You can subscribe to JCP online-only ($86) or print + online ($156 individual).
With your subscription, receive a free PDF collection of the NCDEU Festschrift articles. Hurry! This offer ends December 31, 2011.
If you are a paid subscriber to JCP and do not yet have a username and password, activate your subscription now.
As a paid subscriber who has activated your subscription, you have access to the HTML and PDF versions of this item.
Click here to login.
Did you forget your password?
Still can't log in? Contact the Circulation Department at 1-800-489-1001 x4 or send email
Background: Atypical antipsychotics effectively
reduce maladaptive behavior in individuals with mental
retardation, yet bring significant weight gain and metabolic
anomalies. Ziprasidone, a weight-neutral antipsychotic in
patients with schizophrenia or schizoaffective disorder, has not
been studied in a population with mental retardation and
Method: Forty patients with mental retardation
and maladaptive behaviors who had gained excessive weight or were
inadequately responsive to other agents were switched to
ziprasidone. Weight, total cholesterol, HDL, LDL, triglycerides,
and frequency of maladaptive behavior were recorded at baseline
and after 6 months of ziprasidone treatment.
Results: Ziprasidone treatment was associated
with a significant weight loss of 8.1 lb (3.6 kg) as well as a
significant reduction in total cholesterol and triglycerides
(p<=.05). The monthly frequency of the maladaptive behavior
remained unchanged or improved in 72% (18/25) of the patients in
whom maladaptive behavior was assessed.
Conclusion: Ziprasidone effectively reduces the
frequency of maladaptive behavior in a patient group with mental
retardation without causing weight gain or metabolic